196 related articles for article (PubMed ID: 27225236)
1. Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: a feasibility study.
Inoue S; Kodjebacheva G; Scherrer T; Rice G; Grigorian M; Blankenship J; Onwuzurike N
Int J Hematol; 2016 Aug; 104(2):200-7. PubMed ID: 27225236
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
3. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
[TBL] [Abstract][Full Text] [Related]
4. Use of Wise Device Technology to Measure Adherence to Hydroxyurea Therapy in Youth With Sickle Cell Disease.
Ingerski LM; Loew M; Porter JS; Su Y; Zhang H; Hankins JS; Wang WC
J Pediatr Hematol Oncol; 2021 Jan; 43(1):e19-e25. PubMed ID: 33235145
[TBL] [Abstract][Full Text] [Related]
5. Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10-18 years through community health workers: The HABIT study.
Green NS; Manwani D; Matos S; Hicks A; Soto L; Castillo Y; Ireland K; Stennett Y; Findley S; Jia H; Smaldone A
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643377
[TBL] [Abstract][Full Text] [Related]
6. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS
Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779
[TBL] [Abstract][Full Text] [Related]
7. Improving Medication Adherence with Two-way Short Message Service Reminders in Sickle Cell Disease and Asthma. A feasibility randomized controlled trial.
Pernell BM; DeBaun MR; Becker K; Rodeghier M; Bryant V; Cronin RM
Appl Clin Inform; 2017 May; 8(2):541-559. PubMed ID: 28536723
[TBL] [Abstract][Full Text] [Related]
8. Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia.
Estepp JH; Winter B; Johnson M; Smeltzer MP; Howard SC; Hankins JS
Pediatr Blood Cancer; 2014 Nov; 61(11):2031-6. PubMed ID: 25132074
[TBL] [Abstract][Full Text] [Related]
9. HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol.
Smaldone A; Manwani D; Aygun B; Smith-Whitley K; Jia H; Bruzzese JM; Findley S; Massei J; Green NS
BMC Pediatr; 2019 Oct; 19(1):354. PubMed ID: 31615480
[TBL] [Abstract][Full Text] [Related]
10. Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents.
Reddy PS; Cai SW; Barrera L; King K; Badawy SM
Ann Med; 2022 Dec; 54(1):683-693. PubMed ID: 35234095
[TBL] [Abstract][Full Text] [Related]
11. Medication adherence among pediatric patients with sickle cell disease: a systematic review.
Walsh KE; Cutrona SL; Kavanagh PL; Crosby LE; Malone C; Lobner K; Bundy DG
Pediatrics; 2014 Dec; 134(6):1175-83. PubMed ID: 25404717
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania.
Makubi A; Sasi P; Ngaeje M; Novelli EM; Mmbando BP; Gladwin MT; Makani J
BMC Med Res Methodol; 2016 Oct; 16(1):140. PubMed ID: 27756209
[TBL] [Abstract][Full Text] [Related]
13. Allocation of Treatment Responsibility and Adherence to Hydroxyurea Among Adolescents With Sickle Cell Disease.
Creary SE; Modi AC; Stanek JR; Chisolm DJ; O'Brien SH; Nwankwo C; Crosby LE
J Pediatr Psychol; 2019 Nov; 44(10):1196-1204. PubMed ID: 31403687
[TBL] [Abstract][Full Text] [Related]
14. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease.
Badawy SM; Thompson AA; Penedo FJ; Lai JS; Rychlik K; Liem RI
Eur J Haematol; 2017 Jun; 98(6):608-614. PubMed ID: 28306171
[TBL] [Abstract][Full Text] [Related]
15. Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT) efficacy trial: Community health worker support may increase hydroxyurea adherence of youth with sickle cell disease.
Green NS; Manwani D; Aygun B; Appiah-Kubi A; Smith-Whitley K; Castillo Y; Soriano L; Jia H; Smaldone AM
Pediatr Blood Cancer; 2024 Apr; 71(4):e30878. PubMed ID: 38321562
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
Candrilli SD; O'Brien SH; Ware RE; Nahata MC; Seiber EE; Balkrishnan R
Am J Hematol; 2011 Mar; 86(3):273-7. PubMed ID: 21328441
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27896936
[TBL] [Abstract][Full Text] [Related]
18. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision.
Creary S; Zickmund S; Ross D; Krishnamurti L; Bogen DL
BMC Res Notes; 2015 Aug; 8():372. PubMed ID: 26303306
[TBL] [Abstract][Full Text] [Related]
20. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]